Kura Oncology, Inc. (KURA)
| Market Cap | 1.04B |
| Revenue (ttm) | 104.03M |
| Net Income (ttm) | -216.88M |
| Shares Out | 87.02M |
| EPS (ttm) | -2.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,310,446 |
| Open | 12.02 |
| Previous Close | 11.98 |
| Day's Range | 11.64 - 12.13 |
| 52-Week Range | 5.41 - 12.49 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 25.00 (+109.21%) |
| Earnings Date | Nov 4, 2025 |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for KURA stock is "Buy." The 12-month stock price target is $25.0, which is an increase of 109.21% from the latest price.
News
Kura Oncology: A Cautious Buy
Kura Oncology (KURA) is rated a cautious Speculative Buy, driven by Komzifti's FDA approval and frontline AML potential. KURA's near-term revenue under the current label is meaningful but insufficient...
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, toda...
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data
Kura Oncology remains a Strong Buy, driven by Ziftomenib's differentiated safety profile and significant AML market potential. KURA's Ziftomenib avoids a QTc prolongation boxed warning, offering a pot...
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of canc...
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated AML, is now commercially available in the United States KOMZIFTI, the first and only once-daily FDA-approved m...
Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript
Kura Oncology, Inc. ( KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia November 13, 2025 12:30 PM EST Company Participants Greg Mann Troy Wilson...
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low survival rat...
US FDA approves Kura Oncology's blood cancer therapy
The U.S. Food and Drug Administration has approved Kura Oncology's drug to treat a rare form of blood cancer that has returned or resisted initial therapy, the regulator said on Thursday.
Kura Oncology to Participate in Upcoming Investor Conference
SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines fo...
Kura Oncology, Inc. (KURA) Q3 2025 Earnings Call Transcript
Kura Oncology, Inc. ( KURA) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Greg Mann Thomas Doyle - Senior Vice President of Finance & Accounting Troy Wilson - Chairman, CEO ...
Kura Oncology Reports Third Quarter 2025 Financial Results
– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 –
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
– Milestone triggered by dosing of first patient in the second of two frontline AML Phase 3 clinical trials – – Milestone triggered by dosing of first patient in the second of two frontline AML Phase ...
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting
– Data to be featured in two oral presentations on December 8, 2025 – – Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate use – SA...
Kura Oncology's Ziftomenib Poised For Differentiation
Kura Oncology is reiterated as a strong buy, due to Ziftomenib's potential best-in-class safety profile in NPM1-mutated AML. Recent FDA approval of Syndax's Revuforj included a boxed warning for cardi...
Kura Oncology to Report Third Quarter 2025 Financial Results
SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
- Milestone triggered by dosing of first patient in frontline AML Phase 3 clinical program- SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharma...
Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology Transcript
Kura Oncology, Inc. (NASDAQ:KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology October 18, 2025 1:30 PM EDT Company Participants Troy Wi...
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies Early clinical and preclinical data support darlifarnib's potential to enhance clinical benefit of...
Kura Oncology, Inc. (KURA) Presents at UBS Virtual Oncology Day Transcript
Kura Oncology, Inc. (NASDAQ:KURA) UBS Virtual Oncology Day October 1, 2025 2:30 PM EDT Company Participants Troy Wilson - Chairman, CEO & President Conference Call Participants Xiaochuan Dai - UBS In...
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML –
Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)
– KOMET-017-IC trial of intensive chemotherapy combination will assess MRD negative CR and EFS as dual-primary endpoints to support potential U.S. accelerated and full approval –
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
– KOMET-001 in R/R NPM1-m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses –
Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy
Kura Oncology is rated Buy, driven by a strong cash position, strategic Kyowa Kirin partnership, and a robust, diversified pipeline. KURA's lead asset, Ziftomenib, targets AML and awaits a pivotal FDA...
Kura Oncology, Inc. - Special Call
Kura Oncology, Inc. - Special Call Company Participants Troy Wilson - Chairman, CEO & President Francis Burrows - Chief Scientific Officer Mollie Leoni - Chief Medical Officer Conference Call Particip...